Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.93 |
| ▸ | KIT known ✓ | P10721 | 3/20 | 0.93 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.77 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.77 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.77 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.77 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.77 |
| ▸ | ALK | Q9UM73 | 20/20 | 0.93 |
| ▸ | GAK | O14976 | 1/20 | 0.77 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | ESR1 | P03372 | 1/20 | 0.77 |
| ▸ | PGR | P06401 | 1/20 | 0.77 |
| ▸ | RET | P07949 | 1/20 | 0.77 |
| ▸ | ROS1 | P08922 | 1/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.77 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.77 |
| ▸ | FER | P16591 | 1/20 | 0.77 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14990894 | 1.00 | ALK (0.93) | ALKKDRKITGAKACOX3 | |
| SCHEMBL897477 | 0.96 | ALK (1.00) | ALKKDRKITGAKACOX3 | |
| SCHEMBL897455 | 0.89 | ALK (0.84) | ALKKDRKITGAKACOX3 | |
| SCHEMBL29895703 | 0.88 | ALK (0.84) | ALKKDRKITGAKACOX3 | |
| SCHEMBL896333 | 0.88 | ALK (1.00) | ALKKDRKITGAKACOX3 | |
| SCHEMBL29895704 | 0.88 | ALK (0.84) | ALKKDRKITGAKACOX3 | |
| SCHEMBL29895699 | 0.88 | ALK (0.84) | ALKKDRKITGAKACOX3 | |
| SCHEMBL897896 | 0.88 | ALK (0.84) | ALKKDRKITGAKACOX3 | |
| SCHEMBL897395 | 0.88 | ALK (0.86) | ALKKDRKIT | |
| SCHEMBL897704 | 0.87 | ALK (0.81) | ALKKDRKITGAKACOX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-10 | — | — | US | disclosed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | KDR 71/4885KIT 250/4885EGFR 218/4885 |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | KDR 71/4885KIT 250/4885EGFR 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.